Diabetic Macular Edema Drug Pipeline — PatSnap Eureka
Diabetic Macular Edema Drug Pipeline: Anti-VEGF, Sustained-Release & Kinase Inhibitor Approaches
DME affects approximately one in fourteen people with diabetes globally. The therapeutic landscape is rapidly evolving beyond standard intravitreal anti-VEGF monotherapy toward high-dose extended-interval regimens, gene therapy, dual-pathway biologics, and small molecule kinase inhibitors — with patent activity spanning more than 12 jurisdictions.
Four Dimensions of the Evolving DME Pipeline
Retrieved patent and literature signals reveal a DME landscape moving well beyond standard anti-VEGF monotherapy, spanning biologics, gene therapy, small molecules, and novel delivery platforms. PatSnap's life sciences intelligence platform tracks all four dimensions in real time.
High-Dose Extended-Interval Anti-VEGF Biologics
The largest single cluster in this dataset centers on 8 mg aflibercept administered at extended intravitreal intervals (HDq12, HDq16, HDq20 regimens). Bayer Healthcare LLC holds more than 15 filings across 12+ jurisdictions. Pharmacokinetic modeling shows free aflibercept reaches its lower limit of quantitation approximately 15 weeks post-injection — the pharmacological basis for extended intervals.
Bayer Healthcare LLC · 15+ patentsGene Therapy-Based Sustained Anti-VEGF Delivery
Three distinct strategies appear: AAV-mediated anti-VEGF Fab delivery (RegenxBio Inc.), AAV2-aflibercept gene therapy (Adverum Biotechnologies), and HuPTM anti-hVEGF Fab with α2,6-sialylation (Regenerative Biology Inc.). These aim to provide durable, single-administration alternatives to repeated intravitreal injections.
Preclinical to early clinical stageSmall Molecule Kinase Inhibitors & RTK Inhibitors
A differentiated non-biologic pipeline includes selective RTK inhibitors (Alcon), photoinducible azide-kinase conjugates (Semmelweis University), mTOR inhibitors including rapamycin/sirolimus (Santen Pharmaceutical), PI3K/mTOR dual inhibitor gedatolisib (Celcuity Inc.), plasma kallikrein inhibitors (KalVista), and vicanabine (Roche) — all addressing injection burden.
Multiple mechanisms · 6 patent familiesBispecific & Multi-Target Biologics
Anti-VEGF partial responders (approximately 60–70% of DME patients) drive multi-target strategies. Key approaches include VEGF+ANG2 dual inhibition (Roche), VEGF+complement fusion protein efdamrofusp alfa (Innovent Biologics), and a VEGF+IL-8+ANG2 trispecific aptamer (Daifu Medical). These address vascular destabilization and VEGF-independent pathogenic pathways simultaneously.
Emerging Chinese biopharma IP activityBeyond VEGF: Eight Emerging Targets in DME Pathology
While VEGF remains the dominant target across this dataset — addressed through VEGFR1/VEGFR2 fusion trap proteins, anti-VEGF antibody Fabs, aptamers, and gene therapy vectors — retrieved results highlight a rich landscape of complementary molecular targets that are driving next-generation DME drug development.
Angiopoietin-2 (ANG2) is positioned as a co-driver of vascular destabilization, with Roche's VEGF/ANG2 bispecific antibody patents specifically addressing personalized treatment based on disease biomarkers. Plasma kallikrein, disclosed by KalVista Pharmaceuticals and Dyax Corp., establishes a VEGF-independent mechanism of retinal vascular permeability — providing the rationale for small molecule kallikrein inhibitors as a distinct therapeutic modality. The PatSnap life sciences platform enables systematic tracking of these emerging target families.
Complement pathway activation, addressed by Innovent Biologics' efdamrofusp alfa, is emerging as a co-pathogenic mechanism particularly relevant for treatment-refractory subpopulations. Additionally, the mTOR/PI3K pathway (Santen, Celcuity), PDGF (OSI Eye Tech), ceramide (Michigan State University / Memorial Sloan Kettering), integrin α3β1 (Seoul National University), and NUP153 nuclear pore protein (Yonsei University) all represent active areas of academic and commercial patent activity.
- VEGF-A, PlGF, VEGF-B — primary vasoformative and permeability factors
- Angiopoietin-2 (ANG2) — vascular destabilization co-driver
- Plasma kallikrein — VEGF-independent retinal vascular permeability
- Complement pathway — emerging co-pathogenic mechanism in refractory DME
- mTOR / PI3K — convergent downstream pathway of multiple growth factor receptors
- PDGF — pericyte stabilization target for combination with VEGF blockade
- Ceramide — sphingolipid-driven apoptosis and vascular dysfunction in DR
- NUP153 — novel nuclear-level anti-angiogenic mechanism
DME Pipeline: Patent Activity & Unmet Need at a Glance
Visualising key data signals from the retrieved patent and literature dataset, as analysed via PatSnap Analytics.
DME Pipeline: Patent Filings by Therapeutic Modality
Anti-VEGF high-dose biologics dominate the dataset with 15+ Bayer filings alone; small molecule kinase inhibitors show renewed 2025 momentum.
Anti-VEGF Monotherapy: DME Patient Response Profile
Only 29% of DME patients achieve BCVA improvement at 2 years; 60–70% show incomplete response, representing the multi-target pipeline opportunity.
Bayer 8 mg Aflibercept: Global Jurisdiction Filing Coverage
Bayer's HDq12/16/20 patent prosecution spans 12+ jurisdictions, signalling an aggressive global commercialisation IP strategy for next-generation standard-of-care dosing.
Gene Therapy Pipeline: Development Stage by Assignee
RegenxBio and Adverum gene therapy approaches are at preclinical to early clinical stage; Adverum's CST fluctuation endpoint reference suggests clinical-stage data may be available.
Key Patent Assignees in the DME Drug Pipeline
Commercial IP activity is concentrated among a small number of major pharmaceutical and biotechnology organisations, with emerging Chinese biopharma competition in dual-pathway and aptamer formats. See how IP teams use PatSnap to track competitive portfolios.
Track Competitor IP Filings in Real Time
PatSnap Eureka monitors CN and WO filings from emerging Chinese biopharma assignees alongside established Western portfolios.
What the DME Patent Landscape Means for IP Strategy
Key signals from the retrieved dataset for IP strategists, R&D teams, and competitive intelligence professionals. Explore the full dataset via PatSnap Eureka.
Bayer's HD Aflibercept IP Dominance
Bayer Healthcare LLC's multi-jurisdictional patent prosecution covering 8 mg aflibercept HDq12/16/20 regimens, with filings spanning at least 12 jurisdictions, represents an active effort to establish IP dominance over next-generation standard-of-care dosing. IP strategists should map freedom-to-operate carefully around VEGFR fusion protein dosing claims.
Anti-VEGF Partial Responders: Clearly Articulated Unmet Need
Anti-VEGF partial responders — approximately 60–70% of DME patients per the bispecific aptamer patent's estimate — represent a clearly articulated unmet need driving multi-target strategies. Combination approaches targeting ANG2, complement, PDGF, IL-8, plasma kallikrein, and ceramide alongside VEGF are all represented in this dataset, but most remain at preclinical or early clinical stage.
Where DME Pipeline Candidates Stand Clinically
Retrieved results contain multiple signals of clinical translation across the DME pipeline. The most advanced signal is 8 mg Aflibercept (Eylea HD): Bayer Healthcare LLC's patent family describes specific pharmacokinetic modeling (free aflibercept clearance ~0.3–0.46 mL/day; LLOQ in ocular compartment ~15 weeks post-IVT) and references to "safe and effective" IVT injection claims with "at least similar functional and potentially improved anatomic outcomes" compared to the 2 mg regimen — language consistent with completed Phase 3 clinical trial data. The filing dates (2022–2025) and multi-jurisdictional prosecution are consistent with a post-Phase 3 regulatory submission period.
Regeneron's filings explicitly reference the Diabetic Retinopathy Severity Scale (DRSS) as a clinical endpoint, specifying ≥2-step DRSS improvement criteria and citing specific patient demographics (mean HbA1c ~8.5%, mean BCVA ~82 ETDRS letters, mean CRT ~247 µm) consistent with reported Phase 3 PANORAMA study patient characteristics.
A multicentre study from 27 UK-NHS centres (5,716 NPDR eyes) provides real-world clinical data on the impact of repeated anti-VEGF injections on PDR development, modelled using Cox regression and propensity score matching — constituting direct clinical evidence that anti-VEGF injections reduce PDR risk in routine care. The NIH's National Eye Institute also maintains active DME clinical trial registrations supporting the broader field. For comprehensive patent-to-clinical mapping, PatSnap Analytics connects patent families to clinical trial records automatically.
No clinical data for gene therapy (RegenxBio, Adverum), anti-ceramide antibodies, bispecific aptamers, or most novel small molecule approaches were identified in the retrieved results — confirming these as preclinical to early-stage modalities.
Diabetic Macular Edema Drug Pipeline — key questions answered
VEGF is identified as the primary molecular driver of DME pathology. Breakdown of the inner and outer blood-retinal barriers leads to macular swelling, with capillary degeneration, pericyte loss, and retinal ischemia progressing to the neovascular stage of proliferative diabetic retinopathy. VEGF isoforms are documented as the primary vasoformative and permeability factors underlying both DME and PDR.
The 8 mg dose of aflibercept (VEGF receptor fusion protein) is administered at extended intravitreal intervals (HDq12, HDq16, HDq20 dosing regimens: maintenance doses every 12, 16, or 20 weeks) following an initial loading phase. The mechanism involves VEGFR1/VEGFR2 extracellular domain fusion trapping free VEGF-A, PlGF, and VEGF-B in the vitreous compartment, with ocular pharmacokinetic modeling showing free aflibercept reaching its lower limit of quantitation approximately 15 weeks post-injection.
Retrieved results document that only 29% of DME patients achieve BCVA improvement after two years of anti-VEGF therapy, and that 30–40% show insufficient response to current anti-VEGF monotherapy — motivating the multi-target strategies described in this report.
Three distinct gene therapy strategies appear in the dataset: AAV-mediated anti-VEGF Fab delivery (RegenxBio Inc.), AAV2-aflibercept gene therapy (Adverum Biotechnologies, Inc.), and fully human post-translationally modified (HuPTM) antibody gene therapy delivering anti-hVEGF Fabs with α2,6-sialylation via suprachoroidal or subretinal expression vectors (Regenerative Biology Inc.).
Small molecule kinase inhibitors in the DME pipeline include selective RTK inhibitors (Alcon Inc.), photoinducible azide-containing kinase inhibitors (Semmelweis University), mTOR pathway inhibitors including rapamycin/sirolimus and rapalogs (Santen Pharmaceutical), PI3K/mTOR dual inhibitor gedatolisib (Celcuity Inc.), plasma kallikrein inhibitors (KalVista Pharmaceuticals), and vicanabine, a triazolopyrimidine compound (Hoffmann-La Roche).
Chinese biopharma organizations generating substantive IP in the DME space include Innovent Biologics (Suzhou) Co., Ltd. with the VEGF/complement dual-pathway fusion protein efdamrofusp alfa, Daifu Medical LLC with a bispecific aptamer targeting VEGF, IL-8, and ANG2, and Regenerative Biology Inc. with HuPTM anti-hVEGF Fab gene therapy. Academic researchers and Western biopharma IP teams should monitor CN and WO filings from these assignees as potential competitive or partnership signals.
Still have questions about the DME patent landscape? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About DMEAccelerate Your DME Drug Pipeline Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track anti-VEGF combinations, gene therapy, and kinase inhibitor patent activity across global jurisdictions.
References
- Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders — Bayer Healthcare LLC, 2023, US [Patent]
- Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders — Bayer Healthcare LLC, 2023, EP [Patent]
- Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders — Bayer Healthcare LLC, 2023, WO [Patent]
- Use of a VEGF antagonist to treat angiogenic eye disorders — Regeneron Pharmaceuticals, Inc., 2020, SG [Patent]
- USE OF VEGF ANTAGONISTS TO TREAT ANGIOGENIC EYE DISORDERS — Regeneron Pharmaceuticals, Inc., 2021, ID [Patent]
- Treatment of ocular diseases using recombinant viral vectors encoding anti-VEGF FABs — RegenxBio Inc., 2025, JP [Patent]
- Gene therapy for eye pathologies — RegenxBio Inc., 2021, MX [Patent]
- Methods of treating ocular neovascular diseases using AAV2 variants encoding aflibercept — Adverum Biotechnologies, Inc., 2022, SG [Patent]
- METHOD FOR REDUCING CST FLUCTUATION IN NEOVASCULAR AMD CAUSED BY A RECOMBINANT ADENOASSOCIATED VIRUS — Adverum Biotechnologies, Inc., 2024, BR [Patent]
- Treating diabetic retinopathy with fully human post-translationally modified anti-VEGF Fab — Regenerative Biology Inc., 2022, CN [Patent]
- Personalized treatment of ophthalmologic diseases — F. Hoffmann-La Roche AG, 2021, CA [Patent]
- Methods of treating age-related macular degeneration and diabetic macular edema — Innovent Biologics (Suzhou) Co., Ltd., 2025, WO [Patent]
- Bispecific aptamer compositions for treating retinal diseases — Daifu Medical LLC, 2023, CN [Patent]
- Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-YL]carbonyl)phenyl)-3-[4-(4,6-dimorpholin-4-YL-1,3,5-triazin-2-YL)phenyl]urea — Celcuity Inc., 2025, WO [Patent]
- Novel photoinducible kinase inhibitors for treating proliferative and vasoproliferative diseases — Semmelweis University, 2025, WO [Patent]
- Mtor pathway inhibitors for treating ocular disorders — Santen Pharmaceutical Co., Ltd., 2012, US [Patent]
- Treatments of diabetic macular edema and impaired visual acuity — KalVista Pharmaceuticals Limited, 2022, IL [Patent]
- Dosing regimen for vicanabine — Hoffmann-La Roche, 2025, CN [Patent]
- Diabetic Retinopathy: Mechanism, Diagnosis, Prevention, and Treatment — Queen's University Belfast, 2015 [Academic Paper]
- Diabetic retinopathy: Battling the global epidemic — University of New Mexico, 2016 [Academic Paper]
- Impact of Anti-VEGF Treatment for Diabetic Macular Oedema on Progression to Proliferative Diabetic Retinopathy — UK multicentre study (27 NHS centres, 5,716 NPDR eyes), 2023 [Paper]
- Therapeutic Effect of Abelmoschus manihot on Type 2 Diabetic Nonproliferative Retinopathy and the Involvement of VEGF — Nanjing University of Chinese Medicine, 2020 [Paper]
- Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy — University of Catania, 2022 [Paper]
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Patent data retrieved from PatSnap Eureka's global patent database. This report represents a snapshot of innovation signals within a targeted dataset and should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.